2015
Esx vivo host and parasite response to antileishmanial drugs and immunomodulators
Gonzalez-Fajardo L; Fernández O; McMahon-Pratt D; Gore Saravia N.
2019
Evidence of self-medication with chloroquine before consultation for Malaria in the Southern Pacific Coast Region of Colombia
Diaz G; Lasso M; Montenegro L; Murillo-Solano C; Echeverry D
2014
Evolución de la resistencia antimicrobiana en Bacilos Gram Negativos en Unidades de Cuidado Intensivo en Colombia
Hernández-Gómez C; Blanco VM; Motoa G; Correa A; Maya JJ; de la Cadena E; Perenguez M; Rojas L; Hernández A; Vallejo M; Villegas MV; Grupo de Resistencia Bacteriana Nosocomial en Colombia.
Exploring the role of residue 228 for substrate and inhibitor recognition by VIM Metallo -B-Lactamases
Mojica MF, Mahler SG, Bethel CR, Taracila MA, Kosmopoulou M, Papp-Wallace KM, Llarrull LI, Wilson BM, Marshall SH, Wallace CJ, Villegas MV, Harris ME, Vila AJ, Spencer J, Bonomo RA.
Extended spectrum ?-lactamase producers among Enterobacteriaceae in the Latin American nosocomial setting.
Guzmán-Blanco M; Labarca JA; Villegas MV; Gotuzzo E; on behalf of the Latin America Working Group on Bacterial Resistance
Guzmán-Blanco M; Labarca JA; Villegas MV; Gotuzzo E on behalf of the Latin America Working Group on Bacterial Resistance
2012
Factores que propician la innovación: el caso de la biomedicina.
Pinto L; Gómez L; Saravia NG.
First Identification of OXA-72 Carbapenemase from Acinetobacter pittii in Colombia.
Montealegre MC; Maya JJ; Correa A; Espinal P; Mojica MF; Ruiz SJ; Rosso F; Vila J; Quinn JP; Villegas MV.
2013
First Report of a NMC-A carbapenemase in an Enterobacter cloacae from Colombia
Blanco VM; Rojas LJ; De La Cadena E; Maya JJ; Camargo RD; Correa A; Quinn JP; Villegas MV
First Report of a Pseudomonas aeruginosa Isolate Co-Harboring KPC and VIM Carbapenemases.
Correa A; Montealegre MC; Mojica MF; Maya JJ; Rojas LJ; De La Cadena EP; Ruiz SJ; Recalde M; Rosso F; Quinn JP; Villegas MV.